Christensen et al. 2013. Predicting transition temperature of elastin-like polypeptide fusion proteins. Biomacromolecules.
Kowalczyk et al. 2014. Elastin-like polypeptides as a promising family of genetically-engineered protein based polymers. World Journal of Microbiology and Biotechnology.
McDaniel et al. 2013. A unified model for de novo design of elastin-like polypeptides with tunable inverse transition temperatures. Biomacromolecules.
Vasoactive Intestinal Peptide
Alshafie et al. 2014. VIP regulates CFTR membrane expression and function in Calu-3 cells by increasing its interaction with NHERF1 and P-ERM in a VPAC1- and PKCε-dependent manner. American Journal of Physiology – Cell Physiology.
Hamidi et al. 2011. VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension. Respiratory Research.
Henning and Sawmiller 2001. Vasoactive intestinal peptide: cardiovascular effects. Cardiovascular Research.
Koga et al. 2014. Role of VPAC2 receptor in monocrotaline-induced pulmonary hypertension in rats. .
McNally et al. 2015. Contemporary cardiac issues in Duchenne Muscular Dystrophy. Circulation.
Szema et al. 2013. VIP gene deletion in mice causes cardiomyopathy associated with upregulation of heart failure genes. PLOS ONE.
Almquist et al. 2016 Unraveling the pharmacokinetic interaction of ticagrelor and MEDI2452 (ticagrelor antidote) by mathematical modeling. CPT Pharmacometrics & Systems Pharmacololgy
Buchanan et al. 2015. Structural and functional characterization of a specific antidote for ticagrelor. Blood.
Erlinge 2015. The first specific antiplatelet antidote. Blood